2.
EGFR突变患者与野生型患者的疗效比较
The efficacy of icotinib in EGFR mutation and wild-type patients
| Response | Mutation | Wild-type | P |
| Complete response | 0 (0) | 0 (0) | - |
| Partial response | 63 (63.6)% | 1 (4.0)% | - |
| Stable response | 30 (30.3)% | 5 (24.0)% | - |
| Progressive disease | 6 (6.1)% | 19 (72.0)% | - |
| Response rate | 63.6% | 4.0% | < 0.001 |
| Disease control rate | 93.9% | 24.0% | < 0.001 |
| Median progression-free survival (month) | 10.5 | 1.0 | < 0.001 |